Business Context and Reporting Period
This Form 8-K filing by Bruker Corporation (Delaware) was submitted on March 24, 2010, with the report date of March 24, 2010. The filing addresses a corporate governance matter regarding the composition of the Audit Committee.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance issue and does not contain financial performance data.
Material Changes
Collin D'Silva, an independent director and member of the Audit Committee, resigned from the Audit Committee effective March 9, 2010. He continues to serve as an independent director. Consequently, the Audit Committee now consists of only two members, resulting in non-compliance with Nasdaq Listing Rule 5605(c)(2)(A), which mandates a minimum of three members.
Guidance, Outlook, and Risks
Compliance Status: The Company received notice from Nasdaq on March 25, 2010, confirming the non-compliance status.
Cure Period: Under Nasdaq Listing Rule 5605(c)(4)(B), the Company has a 180-day cure period to regain compliance, expiring on September 7, 2010.
Management Action: The Company intends to fill the vacancy on the Audit Committee as expeditiously as possible before the cure period expires.
Investor Verification Checklist
- Verify the appointment of a new Audit Committee member before the September 7, 2010 deadline.
- Confirm that the new appointee meets the independence and financial literacy requirements of Nasdaq Listing Rules.
- Monitor for any further 8-K filings regarding the status of the Audit Committee composition.